Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround
Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Liver failure in a single patient with a complex medical history resulted in a clinical hold by the FDA, leaving RAPT no choice but to unblind both ongoing ph2 studies. The probability that zelnecirnon caused the hepatic failure is low considering alternative explanations and no prior preclinical/clinical evidence of liver toxicity.
